	US 11,725,035 B2
	Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
Martin Roelsgaard Jakobsen, Risskov (DK); Søren Riis Paludan, Åbyhøj (DK); and Kasper Lisager Jønsson, Aarhus C (DK)
Assigned to STipe Therapeutics ApS, Aarhus C (DK)
Appl. No. 16/323,949
Filed by STipe Therapeutics ApS, Aarhus C (DK)
PCT Filed Aug. 9, 2017, PCT No. PCT/EP2017/070208 § 371(c)(1), (2) Date Feb. 7, 2019, PCT Pub. No. WO2018/029256, PCT Pub. Date Feb. 15, 2018.
Claims priority of application No. PA201670606 (DK), filed on Aug. 9, 2016; and application No. PA201770079 (DK), filed on Feb. 8, 2017.
Prior Publication US 2019/0292236 A1, Sep. 26, 2019
Int. Cl. C07K 14/555 (2006.01); A61P 35/00 (2006.01); A61K 38/21 (2006.01); C07K 14/52 (2006.01); A61K 38/17 (2006.01)

CPC C07K 14/555 (2013.01) [A61K 38/1709 (2013.01); A61K 38/21 (2013.01); A61P 35/00 (2018.01); C07K 14/52 (2013.01)]

8 Claims

1. A method of treating a disorder associated with insufficient stimulator of interferon genes (STING) activity comprising administering to an individual in need thereof a polypeptide having at least 80% sequence identity with a polypeptide selected from the group consisting of SEQ ID NOs: 5-28 to treat a disorder associated with insufficient STING activity, wherein the disorder is cancer or infection.